^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AlloStim (bioengineered allogeneic immune cells)

    i
    Other names: bioengineered allogeneic immune cells, T-Stim cells
    Associations

    News

    Trials
    Company:
    Immunovative
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    1m
    ALIVE: Immunotherapy for Advanced Liver Cancer (clinicaltrials.gov)
    P2/3, N=150, Suspended, Mirror Biologics, Inc. | Trial completion date: Dec 2025 --> Dec 2026 | Recruiting --> Suspended | Trial primary completion date: Aug 2025 --> Nov 2026
    Trial completion date • Trial suspension • Trial primary completion date
    |
    sorafenib • 5-fluorouracil • Lenvima (lenvatinib) • leucovorin calcium • AlloStim (bioengineered allogeneic immune cells)
    1m
    COMUNITY: Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=0, Withdrawn, Mirror Biologics, Inc. | N=50 --> 0 | Trial completion date: Nov 2025 --> Nov 2028 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2025 --> Jun 2028
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    Bavencio (avelumab) • AlloStim (bioengineered allogeneic immune cells)
    2ms
    STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=29, Completed, Mirror Biologics, Inc. | Active, not recruiting --> Completed | Trial completion date: Aug 2025 --> Mar 2025
    Trial completion • Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS wild-type • RAS wild-type
    |
    AlloStim (bioengineered allogeneic immune cells)
    8ms
    AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=12, Completed, Mirror Biologics, Inc. | Phase classification: P2a --> P2
    Phase classification
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    KRAS wild-type • RAS wild-type
    |
    AlloStim (bioengineered allogeneic immune cells)
    8ms
    STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, Mirror Biologics, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Apr 2025 --> Aug 2025 | Trial primary completion date: Nov 2024 --> Mar 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS wild-type • RAS wild-type
    |
    AlloStim (bioengineered allogeneic immune cells)
    11ms
    ALLOPRIME: Universal Anti-Viral Vaccine for Healthy Elderly Adults (clinicaltrials.gov)
    P1/2, N=40, Completed, Mirror Biologics, Inc. | Trial completion date: Apr 2023 --> Nov 2024
    Trial completion date
    |
    AlloStim (bioengineered allogeneic immune cells)
    1year
    COMUNITY: Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Mirror Biologics, Inc. | Trial completion date: Mar 2026 --> Nov 2025
    Trial completion date
    |
    Bavencio (avelumab) • AlloStim (bioengineered allogeneic immune cells)
    1year
    COMUNITY: Combined AlloStim+Anti-PD-L1 in MSS Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Mirror Biologics, Inc. | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial primary completion date • Metastases
    |
    Bavencio (avelumab) • AlloStim (bioengineered allogeneic immune cells)
    over1year
    COMUNITY: Combined AlloStim+Anti-PD-L1 in MSS Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Mirror Biologics, Inc.
    New P2 trial • Metastases
    |
    Bavencio (avelumab) • AlloStim (bioengineered allogeneic immune cells)
    almost2years
    STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=24, Recruiting, Immunovative Therapies, Ltd. | Phase classification: P2b --> P2 | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Nov 2023 --> Nov 2024
    Phase classification • Trial completion date • Trial primary completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS wild-type • RAS wild-type
    |
    AlloStim (bioengineered allogeneic immune cells)
    almost2years
    ALIVE: Immunotherapy for Advanced Liver Cancer (clinicaltrials.gov)
    P2/3, N=150, Recruiting, Immunovative Therapies, Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    sorafenib • 5-fluorouracil • Lenvima (lenvatinib) • leucovorin calcium • AlloStim (bioengineered allogeneic immune cells)
    almost3years
    STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2b, N=24, Recruiting, Immunovative Therapies, Ltd. | Trial completion date: Sep 2023 --> Apr 2024 | Trial primary completion date: Mar 2023 --> Nov 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS wild-type • RAS wild-type
    |
    AlloStim (bioengineered allogeneic immune cells)